Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | FRK | P42685 | 1/20 | 0.35 |
| ▸ | BLK | P51451 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108132 | 0.88 | CA12 (0.40) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL9105963 | 0.87 | CYP17A1 (0.40) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL9104422 | 0.84 | MAPK14 (0.36) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL31422624 | 0.84 | CA12 (0.38) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL30781533 | 0.81 | ACSS2 (0.37) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL22162968 | 0.79 | CA12 (0.44) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL9105837 | 0.78 | CA12 (0.41) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL9118465 | 0.77 | ADORA2A (0.41) | DGAT1CA12CA1CA9CYP17A1 | |
| SCHEMBL9104904 | 0.77 | SUV39H2 (0.40) | DGAT1CA12CA1CA9BRD4 | |
| SCHEMBL9104899 | 0.76 | ACHE (0.40) | DGAT1CA12CA1CA9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | DGAT1 3204/4885CA12 4084/4885CA1 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.